| Bioactivity | TCID (4,5,6,7-Tetrachloroindan-1,3-dione) is a potent and selective neuronal ubiquitin C-terminal hydrolase (UCH-L3) inhibitor with an IC50 of 0.6 μM[1]. TCID diminishes glycine transporter GlyT2 ubiquitination in brainstem and spinal cord primary neurons[2]. | ||||||||||||
| Target | IC50: 0.6 μM (UCH-L3) and 75 μM (UCH-L1) | ||||||||||||
| Invitro | TCID (4,5,6,7-Tetrachloroindan-1,3-dione; compound 11) inhibits UCH-L1 with an IC50 of 75 μM[1]. TCID (10 μM; 1, 2 hours) diminishes glycine transporter GlyT2 ubiquitination in brainstem and spinal cord primary neurons[2]. | ||||||||||||
| Name | TCID | ||||||||||||
| CAS | 30675-13-9 | ||||||||||||
| Formula | C9H2Cl4O2 | ||||||||||||
| Molar Mass | 283.92 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Liu Y, et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cellline. Chem Biol. 2003 Sep;10(9):837-46. [2]. de Juan-Sanz J, et al. Constitutive endocytosis and turnover of the neuronal glycine transporter GlyT2 is dependent on ubiquitination of a C-terminal lysine cluster. PLoS One. 2013;8(3):e58863. |